Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25798826 | 0.82 | CETP (0.59) | CETPKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL5796215 | 0.80 | MC4R (0.54) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL4358357 | 0.80 | SMPD1 (0.43) | CETPKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL4824563 | 0.79 | CYP1A2 (0.44) | CETPKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL6798515 | 0.79 | NPC1 (0.54) | CETPKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL4364804 | 0.78 | MC4R (0.44) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3891823 | 0.76 | LMNA (0.55) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL5561274 | 0.76 | PTGDR2 (0.43) | ALDH1A1LMNAMAPK1MEN1KMT2A | |
| SCHEMBL24953242 | 0.75 | CETP (0.71) | CETPKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL29625758 | 0.75 | CETP (0.71) | CETPKDM4EALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1408986-B1 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7312246-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1594512-A4 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | KEMIA INC (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1408986-A4 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1594512-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | Kemia, INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050215563-A1 | Proteomimetic compounds and methods | YALE UNIVERSITY | 2005-09-29 | — | — | US | disclosed |
| US-6858600-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040248850-A1 | Compounds for the treatment of HIV infection | KEMIA, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004071426-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | KEMIA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1408986-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030008882-A1 | Proteomimetic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002089738-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248850-A1 | Compounds for the treatment of HIV infection | CCR5, CD4, HAVCR2 | CETP 322/4885KDM4E 2338/4885ALDH1A1 1251/4885 |
| US-20030008882-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | CETP 301/4885KDM4E 4750/4885ALDH1A1 4826/4885 |
| US-20050215563-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | CETP 301/4885KDM4E 4750/4885ALDH1A1 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.